Drugs & Therapy Perspectives

, Volume 17, Issue 5, pp 6–9 | Cite as

Augmentation strategies in resistant depression — some are effective and well tolerated

New drugs and disease management


Nicotine Smoking Cessation Fluoxetine Bupropion Nicotine Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998; 19(6): 455–64PubMedCrossRefGoogle Scholar
  2. 2.
    Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry 2000; 61 (Suppl. 2): 13–9PubMedGoogle Scholar
  3. 3.
    Mischoulon D, Nierenberg AA, Kizilbash L, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000 Jun; 45: 476–81PubMedGoogle Scholar
  4. 4.
    Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–6PubMedCrossRefGoogle Scholar
  5. 5.
    Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307–14PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenbaum JF, Fava M, Nierenberg AA, et al. Treatment-resistant mood disorders. In: Gabbard GO, editor. Treatment of psychiatric disorders. 2nd ed. Washington DC: American Psychiatric Press, 1995: 1276–94Google Scholar
  7. 7.
    Hullet FJ, Bidder TG. Phenelzine plus triiodothyronine combination in a case of refractory depression. J Nerve MentDis 1983; 171: 318–20CrossRefGoogle Scholar
  8. 8.
    Stein D, Avni J. Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand 1988; 7: 623–36CrossRefGoogle Scholar
  9. 9.
    Ereshefsky L. Drug-drug interactions involving antidepressant: focus on venlafaxine. J Clin Psychopharmacol 1996; 16: 37S–53SPubMedCrossRefGoogle Scholar
  10. 10.
    Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32: 1–21PubMedCrossRefGoogle Scholar
  11. 11.
    Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. Annal Clin Psychiatry 1991; 3: 209–13CrossRefGoogle Scholar
  12. 12.
    Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81–9PubMedCrossRefGoogle Scholar
  13. 13.
    Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997 May 13; 349(9065): 1594–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations